BioSpace News Archive

On the heels of a series of successful virtual webinars, The Sickle Cell Foundation of Tennessee will launch the Sickle Cell Today podcast on the KUDZUKIAN Network. The first of the four episode series debuted on Monday, August 10 th and will air once a week going forward. Episodes will focus on pain management, quality of li

Elemental Enzymes, a St. Louis biotechnology firm, has obtained the first patent for a natural peptide solution that is field-proven to treat Citrus Greening disease.

This notice has been updated to advise that the outbreak appears to be over and the outbreak investigation has been closed.

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases, today reported financial results for its fiscal first quarter ended June 30, 2020. Immunovant ended the quarter with approximately $280.3 million in cash. Financial Highlights for Fiscal First Quarter ended June 30, 2020: R&D Expenses: Research and development expenses decreased by $1.6 mi

ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves, today announced unaudited financial results for the quarter ended June 30, 2020. Product Sales Results: Total product sales increased by 9%, or $256,000, to $3 million during the three-m

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the second quarter ended June 30, 2020. Second Quarter 2020 and Recent Business Highlights Announced exclusive license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in Greater China and South Korea;

NL-201 IND submission anticipated during fourth quarter of 2020 Recent financing raises $71.4M in net proceeds to enable broad NL-201 clinical plan and product pipeline development into 2023 Company to host Conference Call Today, August 12, 2020 at 1:30 p.m. Pacific / 4:30 p.m. Eastern SEATTLE, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a Biologics License Application (BLA) for evinacumab as an adjunct to other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH).

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the second quarter 2020 and provided a corporate and commercial update.

MediRevv, a leading Iowa-based revenue cycle management company, announced it has assumed the rank of No. 1935 in Inc. Magazine’s annual Inc. 5000 list—the most prestigious ranking of the nation’s fastest-growing private companies